FOLH1 and prostate carcinoma: Preliminary experiments confirmed that PSMA-positive prostate cancer cells demonstrated a specific uptake of both 64Cu-cudotadipep and 64Cu-cunotadipep, while PSMA-negative prostate cancer cells showed a relatively low uptake of both compounds.